Pacific Biosciences Of California (PACB) Operating Income (2010 - 2026)

Pacific Biosciences Of California's Operating Income history runs 17 years deep, the most recent figure standing at -$8.4 million for Q1 2026.

• In Q1 2026, Operating Income rose 98.05% year-over-year to -$8.4 million; the TTM figure through Mar 2026 stood at -$133.3 million (up 83.78% YoY), while the FY2025 annual figure was -$553.9 million, down 16.77% from the prior year.
• Operating Income was -$8.4 million for Q1 2026 at Pacific Biosciences Of California, up from -$41.2 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$8.4 million in Q1 2026 to a low of -$428.9 million in Q1 2025.
• Historically, Operating Income has averaged -$98.7 million across 5 years, with a median of -$77.5 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Operating Income plunged 427.19% in 2025, then jumped 98.05% in 2026.
• A 5-year view of Operating Income shows it stood at -$87.1 million in 2022, then dropped by 0.53% to -$87.5 million in 2023, then tumbled by 74.79% to -$153.0 million in 2024, then surged by 73.08% to -$41.2 million in 2025, then surged by 79.71% to -$8.4 million in 2026.
• The last three Operating Income figures came in at -$8.4 million (Q1 2026), -$41.2 million (Q4 2025), and -$38.9 million (Q3 2025), per Business Quant data.